MELBOURNE, AUSTRALIA & ST. GALLEN, SWITZERLAND-- March 03, 2022 -- Regulatory News:

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR

CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited (ASX: CSL; USOTC: CSLLY), today announced the provisional notice of the interim result of its public tender offer to acquire all publicly held shares of Vifor Pharma Ltd. (SIX:VIFN; ISIN:CH0364749348) for USD 179.25 per share as indicated in the offer prospectus of 18 January 2022.

According to the provisional interim result, taking into account the Vifor Pharma shares held by the offeror and the persons acting in concert with the offeror at the end of the main offer period and the Vifor Pharma shares tendered during the main offer period, CSL's participation at the end of the main offer period on 2 March 2022 amounts to a total of 74 percent of all listed Vifor Pharma shares as of 2 March 2022, subject to the completion of the offer. CSL highly appreciates this strong support of the combination with CSL by the Vifor Pharma shareholders. If the definitive numbers will be substantially the same as or higher than the preliminary numbers, the offeror plans to waive the 80 percent acceptance rate condition and to declare the offer successful in the definitive notice of the interim result, which is expected to be published on March 8, 2022.

The provisional notice of the interim result is available at www.csltransaction.com.

If the offer is declared successful by the offeror in the definitive notice of the interim result, the additional acceptance period of 10 trading days for the subsequent acceptance of the tender offer is expected to commence on 9 March 2022 and to expire on 22 March 2022, 4 p.m. Swiss time.

The regulatory approval process in relation to the offer is on track and CSL is highly confident that the remaining conditions will be satisfied such that the settlement of the offer may occur around mid-2022 as previously indicated. As described in the offer prospectus, following closing, CSL plans to pursue an application to SIX Exchange Regulation for the delisting of the Vifor shares.